Consensus Arvinas, Inc.

Stocks

ARVN

US04335A1051

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
7.860 ^USD	-0.51%		+1.81%	-33.73%

10-07	Arvinas, Inc. Presents Novel Data From Phase 1 Clinical Trial Of ARV-102 In Patients With Parkinson?s Disease	CI
09-28	Arvinas, Inc. Announces First Participant Dosed in Phase 1/2 Clinical Trial of Arv-6723	CI

Evolution of the Average Target: Arvinas, Inc.

Evolution of the Target Price: Arvinas, Inc.

Changes in Analyst Recommendations: Arvinas, Inc.

7ceb23c2413c00f998ebc3e6836f.246LQwJmGKsygUMONlt0d822Wdg2bcx3l2WaFzqe5do.msXjCUMCKsJL6iFrRGkCOrnMaehlD6AC5hatbgP1sO-I2eUpQTdiyH_wcw~c842b41bbbe53b7a1dcad94790763bf4

Analysts' recommendations: Arvinas, Inc.

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating	MT
08-04	Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating	MT
05-14	BofA Securities Raises Price Target on Arvinas to $16 From $14	MT
02-24	Wedbush Lifts Price Target on Arvinas to $11 From $9, Keeps Neutral Rating	MT
01-06	Citigroup Upgrades Arvinas to Buy From Neutral, Adjusts Price Target to $15 From $10	MT
20/10/25	Arvinas, Inc. Announces New Patient-Reported Outcomes Data from the Phase 3 Veritac-2 Clinical Trial Evaluating Vepdegestrant	CI
15/10/25	Goldman Sachs Downgrades Arvinas to Sell From Neutral, Cuts Price Target to $6 From $8	MT
18/09/25	Wedbush Cuts Price Target on Arvinas to $9 From $10, Keeps Neutral Rating	MT
08/08/25	Truist Cuts Price Target on Arvinas to $10 From $11, Keeps Hold Rating	MT
07/08/25	Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating	MT
07/08/25	Morgan Stanley Lowers Price Target on Arvinas to $10 From $11, Keeps Equalweight Rating	MT
06/08/25	Arvinas Q2 revenue falls 71%, net loss widens	RE
15/05/25	UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating	MT
09/05/25	Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating	MT
05/05/25	Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21	MT
02/05/25	Jefferies Downgrades Arvinas to Hold From Buy, Adjusts Price Target to $10 From $52	MT
02/05/25	TD Cowen Downgrades Arvinas to Hold From Buy	MT
09/04/25	Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating	MT
13/03/25	Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70	MT
12/03/25	Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57	MT
11/03/25	Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating	MT
11/03/25	Oppenheimer Downgrades Arvinas to Perform From Outperform	MT
12/02/25	Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating	MT
31/10/24	UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARVINAS, INC.					+76.31%
	WUXI APPTEC CO., LTD.					+41.6%
	ARGENX SE					+24.9%
	LONZA GROUP AG					+8.71%
	IQVIA HOLDINGS INC.					+12.62%
	BEONE MEDICINES AG					+17.47%
	REVOLUTION MEDICINES, INC.					+36.04%
	GENMAB A/S					+1%
	CELLTRION, INC.					+42.98%
	WUXI BIOLOGICS (CAYMAN) INC.					+33.85%
	Average					+29.55%
	Weighted average by Cap.					+24.38%